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ADP-Ribosyl Cyclase: Crystal Structures
Reveal a Covalent Intermediate
ribosyl cyclase catalyze similar reactions, and the amino
acid sequences are 30% identical. In the dimer, the
substrate binding grooves are turned inward toward a
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hidden from the solvent. It has been suggested that aCornell University
Ithaca, New York 14853 channel, which is formed in the dimer, provides access
to the catalytic core for substrates. The channel is large2 Department of Pharmacology
University of Minnesota enough for products and reagents, as well as water and
various ions, so it is unlikely that hydrolysis of intermedi-Minneapolis, Minnesota 55455
ates is blocked by the constraints of the channel space
topology. Moreover, channel access would of course
be required for mechanism-based inhibitors which haveSummary
been shown to block cyclization in CD38 (Sauve and
Schramm, 2002).ADP-ribosyl cyclase catalyzes the elimination of nico-
Here we report the crystallographic structures of ADP-tinamide from NAD and cyclization to cADPR, a known
ribosyl cyclase covalently bound to C3 of ribose-5-second messenger in cellular calcium signaling path-
phosphate (R5P), in complex with pyridylcarbinol andways. We have determined to 2.0 A˚ resolution the
nicotinamide respectively. In addition, the native cyclasestructure of Aplysia cyclase with ribose-5-phosphate
structure was determined to 1.7 A˚ resolution, which isbound covalently at C3 and with the base exchange
the highest resolution to date for the cyclase family, andsubstrate (BES), pyridylcarbinol, bound to the active
the structure of the Glu179Ala cyclase mutant was alsosite. In addition, further refinement at 2.4 A˚ resolution
solved. The kinetic competence of cyclase to hydrolyzeof the structure of nicotinamide-bound cyclase, which
nicotinamide mononucleotide to R5P and nicotinamidewas previously reported, reveals that ribose-5-phos-
was demonstrated by HPLC analysis. Based on a struc-phate is also covalently bound in this structure, and a
tural overlay of conserved residues, it appears that thesecond nicotinamide site was identified. The struc-
overall topology of the dimer protects the substratetures of native and mutant Glu179Ala cyclase were
binding surfaces from proteolysis and blocks nonspe-also solved to 1.7 and 2.0 A˚ respectively. It is proposed
cific access to the active site. In contrast to structuresthat the second nicotinamide site serves to promote
which were previously reported (Prasad et al., 1996;cyclization by clearing the active site of the nicotin-
Yamamoto-Katayama et al., 2002), the R5P ribose ringamide byproduct. Moreover, a ribosylation mechanism
is covalently linked to Glu179, the so-called catalyticcan be proposed in which the cyclization reaction pro-
residue of the BES-bound structures, so that the interac-ceeds through a covalently bound intermediate.
tion of ribose-5-phosphate with a site adjacent to the
pyridylcarbinol and nicotinamide site is revealed, and
Introduction an enzymatic mechanism can be proposed which in-
cludes a covalent intermediate.
ADP-ribosyl cyclase catalyzes the elimination of nicotin-
amide from NAD and the production of second messen-
ger cADPR (Lee et al., 1994 and reviewed in Lee, 2001). Results and Discussion
cGMP-activated kinase can stimulate the cyclase activ-
ity (Willmott et al., 1996), which is essential to the pro- Overview of the Structure
cess of calcium-induced calcium release (CICR), a key The structures of ADP-ribosyl cyclase with bound pyri-
component of the calcium signaling mechanism which dylcarbinol or nicotinamide BES (Munshi et al., 1999)
controls cellular development. The propagation of this are highly similar to those of mutant and native cyclase,
calcium signal component has been studied in sea ur- except that no reagents were bound to the active site
chin egg preparations (Lee 1991, 1996; Lee et al., 1995), in either the mutant or native case. Although the 1.7 A˚
and cyclase has been implicated in CICR potentiation resolution structure was obtained from crystals grown
(Lee et al., 1993, 1995). The enzyme is a 29 kDa protein in the presence of NGD, no bound substrate was found,
and crystallizes as a functionally relevant dimer (Prasad and this structure is considered as native cyclase. In the
et al., 1996), and is similar to BST-1, a cell surface anti- case of the BES-bound structures, cyclization substrate
gen which has been implicated in severe rheumatoid reagents were not added to the crystallization mixture,
arthritis (Kaisho et al., 1994; Dong et al., 1994; Itoh et so that the bound substrate or R5P was apparently co-
al., 1994; Yamamoto-Katayama et al., 2002). The cyclase purified with the protein; in the absence of nicotinamide
dimer is a model for surface antigen CD38, which may or pyridylcarbinol, the R5P was apparently hydrolyzed
play a role in various immune system functions (States away. A similar effect has been observed with the NAD-
et al., 1992; Jackson and Bell, 1990; Harada et al., 1993; dependent deacetylase enzyme, SIR2: BES favors the
Koguma et al., 1994; Li et al., 1994). CD38 and ADP- accumulation of a covalent intermediate (Sauve and
Schramm, 2003). The current structures are all similar
to the first crystallographic structure of cyclase (Prasad*Correspondence: qh22@cornell.edu (Q.H.), leehc@tc.umn.edu (H.C.L.)
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Figure 1. Conserved Structure
The cyclase dimer is shown in a stereo diagram. Residues shown in red are highly conserved in a sequence alignment of ADP ribosyl cyclase,
BST-1, and CD38. Disulfide bonds are shown in green, and they are also conserved. Sequences of various cyclase (cyc), BST-1 (bst), and
CD38 (cd38) molecules are shown in a truncated aligned stack with highly conserved residues shown in red. It is clear that many conserved
residues are clustered near the catalytic cleft of each monomer. The figure was rendered with the program PyMOL (http://pymol.sourceforge.net).
et al., 1996; Munshi et al., 1999) and to each other with the N- and C termini of the protein (Figure 2), an  unit
and an  unit. The handler provides most of the bindingC rms differences of about 1 A˚ or less, and somewhat
similar to the recently solved structure of BST-1 (Yama- surface for the bulky side chains of the substrate and
so determines the relative specificity of the enzyme. Keymoto-Katayama et al., 2002) with a C rms difference
of about 3.5 A˚. With respect to these earlier structures, residues of the handler are nestled deep in the dimeric
cavity and cleft, and such an arrangement would impedeimprovements in crystallographic resolution together
with crucial differences of bound substrates are found proteolysis affecting enzymatic activity, and block non-
specific access to the hydrolyzing power of the activein the current structures.
A careful delineation of the dimeric topology and sub- site.
Although the  and  units are less conserved thandomain structure of the cyclase monomer assists with
the mechanistic interpretation of its enzyme activity. A the handler, those residues which are conserved are
clustered in regions of dimer interaction or scaffoldingstructural overlay of sequence similarity data within the
cyclase family (comprising cyclase, CD38, and BST-1) for the handler unit. In addition, the loops of both the 
and  units contain conserved disulfide bonds, whichshows that conserved residues are clustered in the di-
meric cavity, especially in the substrate binding clefts hold the domains securely, and are likely to impede
proteolysis of the exterior loops. Loops 1 and 2 of the (Figure 1). This region of the protein corresponds to a
region that we have called the “substrate handler,” and unit both have conserved regions, which provide crucial
underpinning for the handler unit, while helices B andit encompasses most of the individual residues which
have been found to affect enzymatic activity. This han- C are more divergent. With a deeply buried  strand, the
 unit provides extensive scaffolding, so that residuesdler is intermediate between two large subdomains at
Covalent Intermediate in ADP-Ribosyl Cyclase
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Figure 2. Subdomain View of Cyclase with
Schematic Representation
The cyclase dimer is shown in a ribbon dia-
gram with key structural components colored
blue to green to red to gray from the N to the
C terminus. Within one of the two cyclase
molecules in the symmetrical dimer, residues
which appear to play a role in the enzymatic
activity are shown in stick representation. A
convenient schematic view shows the color-
ing scheme that we have used for cyclase
subdomain structure in the current study.
Glu179 and Trp140 can be positioned precisely for catal- Strikingly, R5P is largely buried in the core of the
substrate binding groove and interacts with residuesysis (Figure 3). A C-terminal helix bridges the dimer tail
with conserved interactions. which are thought to be critical to the catalytic function
Figure 3. Cyclase Active Site with Bound Substrates, R5P, Pyridylcarbinol, and Nicotinamide
The three domains of ADP ribosyl cylcase are shown in ribbon representation and colored from N to C, blue, green, and red respectively.
Key residues of the active site are shown in ball-and-stick representation, with the atoms colored as follows: C, yellow; N, blue; O, red; and
P, violet. In the structure, R5P is covalently linked at the C3 atom of the ribose ring to a carboxylate O of E179. The BES, pyridylcarbinol
(PYC, left) or nicotinamide (NCA1, right), makes contact with E98 and is bound to W140 in the catalytic cleft. At right, W111 forms a second
nicotine amide site (NCA2), which may shunt nicotine amide away from the active site in the course of the ADPr cyclization reaction. Together
with the absence of bound R5P in the active site of the native structure, the results of this study show how BES compounds block cyclization
and hydrolysis of the covalent intermediate. The figure was rendered with the program Povscript (http://dipsy.biochem.med.umich.edu/
peisach/povscript/) (see Kraulis, 1991).
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Figure 4. Schematic Representation of Cyclase Ligands and Reaction Mechanism
The interaction of cyclase residues with R5P-Glu179 and pyridylcarbinol (Pyc) are shown in a schematic representation (top). The figure was
made with Ligplot (Wallace et al., 1995). The proposed reaction mechanism is also shown. The covalent intermediate in the current structure
apparently accumulates when there is an excess of nicotinamide or pyridylcarbinol, which blocks the cyclization step.
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of the enzyme. The sugar group interacts with the main
chain amine of Trp77 and the phosphate interacts with
the sidechain of S78, so that R5P is held away from the
hydrophobic sidechain of Trp77. Moreover, the cova-
lently linked Glu-R5P residue spans a helix comprising
residues 173–180, which interacts with the sugar residue
along its length, and the phosphate group forms two
hydrogen bonds with the N terminus of the helix (Figure
4). Although it is likely that the formation of the C3
covalent bond to Glu179 results in the elimination of the 3
hydroxyl, it is visible in the map and included in the
structure. The appearance of this hydroxyl group in the
electron density is probably due to the presence of a C1
or C2 bound covalent intermediate at lower occupancy
(see Structural Analysis section below), which could not
be distinguished from the C3 bound intermediate ob-
served in the current structure at the resolution of the
data. Thus, it appears that the handler and  unit struc-
tures of cyclase provide for precise geometric orienta-
tion of the substrate and catalytic residues.
Hydrolysis of Nicotinamide Mononucleotide
The finding of R5P covalently bound to Glu179 is unex-
pected, and the substrate was apparently copurified
with the enzyme. Although this observation of R5P might
be explained as disorder in the second phosphate and
purine group of a bound NAD, it is also possible that R5P
Figure 5. Hydrolysis of NMN to R5P Catalyzed by Cyclase
is derived from the hydrolysis of nicotinamide mono-
(A) NMN (0.1 mM) was incubated with the cyclase (1 g/ml) at pH
nucleotide (NMN), which cannot undergo the cyclization 5 (20 mM sodium acetate) for 3 hr at room temperature. Samples
reaction. The competence of cyclase to catalyze the were analyzed by reversed phase HPLC on a C18 column.
hydrolysis of NMN was tested by HPLC analyses as (B) The time course of the release of R5P was measured by stopping
aliquots of the reaction mixture with equal volume of charcoal (2%shown in Figure 5. After incubation of NMN with the
in 20 mM Tris-base and 2 mM MgCl2). The activated charcoal boundcyclase, a portion was indeed hydrolyzed to nicotin-
up the NMN but not the product, R5P. After centrifuging for 5 minamide (Figure 5A). This was further confirmed by mea-
in a microfuge, the supernatants containing R5P released by the
suring the time course of release of R5P from NMN hydrolysis reaction were recovered and treated with alkaline phos-
during the hydrolysis reaction as shown in Figure 5B. phatase (10 U/ml) for 1 hr at 37C. The amount of phosphate liberated
Cyclase is a multifunctional enzyme capable of using from R5P was measured using the standard Malachite Green assay
for inorganic phosphate.different substrates, NAD and NADP, to produce struc-
turally distinct products, cADPR and NAADP, respec-
tively (Aarhus, et al. 1995). It is thus not surprising that the observed R5P, a reaction which is probably unre-
it can also catalyze the hydrolysis of NMN to R5P. In- lated to cyclization, but which might be expected to
deed, a similar hydrolysis reaction has been shown to be occur in the time required for crystallization. It remains
catalyzed by CD38 (Sauve and Schramm, 2002; Sauve et unclear whether the trailing density results from a resid-
al., 2000), the mammalian homolog of the cyclase. The ual amount of nonhydrolyzed diphosphate, NMN, or flex-
covalently bound R5P observed in the cyclase crystals ibility in the second phosphate with resulting disorder
thus represents the first and definitive evidence that this in the purine group of a bound NAD molecule. The C3-
hydrolysis reaction occurs via a covalent intermediate. Glu179 bond probably results from an intramolecular
rearrangement that occurs between the ribose ring and
the carboxylate moiety, when cyclization is blocked byStructural Analysis
A key feature of the pyridylcarbinol- and nicotinamide- pyridylcarbinol-class BES. When the substrate is pres-
ent and unblocked, cyclization proceeds via the elimina-bound structures is the presence of R5P covalently
bound to Glu179, the “catalytic residue” (Sauve et al., tion of the carboxylate oxygen of Glu179 at C1 of R5P,
and the product is released. This is the end state ob-2000). It may appear as puzzling that the covalent bond
to Glu179 occurs at the C3 position of R5P, as the served in the crystals grown with NGD, where neither
nicotinamide nor pyridylcabinol was added, and cova-proposed reaction mechanism involves C1 (Figure 4).
We propose that the existence of the C3-Glu179 bond lently bound R5P was not observed. (It should be noted
that R5P binding was not observed in the Glu179Alaimplies that covalent bond chemistry can also proceed
with Glu179 at C2 and C1 (Figure 6); a possibility that mutant structure either.) Overall, these results are con-
sistent with the notion that cyclization proceeds throughfinds support from analogous reactions in acetyl ADPR
(Sauve et al., 2001). It is also notable that the electron a covalently bound intermediate at Glu179. Moreover,
these structures together show that the covalent inter-density trails off near the phosphate group (Figure 7).
Hydrolysis of the diphosphate bond of NAD would yield mediate can be captured using a BES, because BES
Structure
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Figure 6. Two Proposed Mechanisms to
Form 3 Intermediate
The observed 3 intermediate may be derived
by at least two possible mechanisms, nonhy-
drolysis (blue) or hydrolysis (red). Hydrolysis
is thought to occur at the 1 position, but it
is likely that certain analogous reactions can
occur at the 2 and 3 positions as shown in
the pathway to the right. It is also plausible
that the intermediate pathway is an internal
rearrangement that occurs without hydroly-
sis, shown at left, which is supported by simi-
lar 2 and 3 substitutions that occur in
AADPR (Sauve et al. 2001). It should be noted
that the 1 hydroxyl is left in the up posi-
tion via hydrolysis, but in the down position
via internal rearrangement. From a mechanis-
tic standpoint, this difference might clarify
whether base exchange substrates block hy-
drolysis versus product release. Unfortunately,
hydroxyl groups did not refine well in either
configuration, and we are not able to distin-
guish these two possibilities at the current
resolution of the data.
appears to block cyclization, and the covalent intermedi- reaction (Graeff et al., 2001). In cyclase and in the CD38
model, the carboxylate group of Glu98 directly opposesate was not observed in the absence of BES. This con-
clusion is congruent with the similar effect of mecha- C1 and C2 of the ribose ring with respect to Glu179
of the enzyme, and these moieties together form a geo-nism-based inhibitors on CD38 (Sauve and Schramm,
2002). Thus, it is now clear that covalent intermediate metric reaction plane (Figure 3). The Glu98 is a strong
hydrogen bond acceptor because the charged group iscatalysis occurs in the course of the cyclization and
base exchange reactions in the active site of Aplysia mostly buried in the core of the enzyme beneath Trp77,
and also geometrically stabilized by an internal saltcyclase.
Comparison of high-resolution structures together bridge to His85. It is therefore likely that Glu98 provides
stabilization for the hydrolysis reaction and for nicotin-with identification of the cyclase mechanism leads to a
profound understanding of the residues that participate amide elimination at ribose C1 by Glu179. Glu98 is also
part of the nicotinamide binding site in the current struc-in the global reaction, and helps to explain the biochemi-
cal differences in the cyclase enzyme family. Homology- ture and in BST-1 as well (Yamamoto-Katayama et al.,
2002). The pyridylcarbinol-bound structure shows thebased models of CD38 constructed using the 3D-PSSM
program (Kelley et al., 2000) assisted with this compari- interaction of Glu98 with the amine group of the aromatic
ring in a manner similar to nicotinamide. After nicotin-son (Figure 8). Cyclase residue Glu98 is conserved in
CD38, but it appears as serine or cysteine in BST-1, and amide release, the purine group of the substrate must
take its place in the binding site in order for cyclizationthis variable residue also appears to be involved in the
Covalent Intermediate in ADP-Ribosyl Cyclase
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Figure 7. Electron Density Map
Ribose-5-phoshate (R5P) is covalently bound to Glu179, so that the residue spans a critical helix of the cyclase enzyme. In addition, the
ribose ring makes contact with a nearby tryptophan residue (Trp77). In the top two panels, the final 2Fo-Fc electron density map, 1 , was
calculated with the the program CNS (Bru¨nger et al., 1998). In the middle panel, pyridylcarbinol (Pyc) is shown bound to Trp140 and Glu98.
In the lower panel, a simulated annealing Fo-Fc omit map (pink) was calculated with R5P, Pyc, and an adjacent water molecule deleted from
the structure. The omit map is shown at 1.7 . The figure was rendered with the program PyMOL (http://pymol.sourceforge.net).
to occur. Glu98 and Trp140 probably position the purine amide binding with respect to other BST-1 and cyclase,
and to hydrolysis of the substrate at C1 of the ribosegroup of the substrate for nucleophilic attack on C1 of
the ribose ring, leading to elimination of the carboxylate ring.
Another feature of the enzyme which might affect cy-oxygen of Glu179. Thus, Glu98 would promote cycliza-
tion of the substrate in a manner consistent with the clization is the presence of a second nicotinamide bind-
ing site adjacent to the catalytic cleft. The second nico-formation of a covalent intermediate at Glu179 of the
enzyme so long as the active site can be cleared of tinamide molecule is bound to Trp111 of the enzyme in
the original cyclase structure (Figure 3), and the occu-nicotinamide. (Similar arguments can be made in regard
to residue Glu78 of BST-1, which would appear to block pancy of this nicotinamide site appears to be higher
than that of the initially observed site at Trp140 (whichthe phosphate interactions with the N terminus of the
adjacent helix which are observed in cyclase and the also corresponds to the pyridylcarbinol site). In BST-1
and in the CD38 model, this site is blocked by V136 andCD38 model [Figure 8].) In this scheme, Glu 98 is a
crucial residue for cyclization and nicotinamide binding I133 respectively. It might be expected that a second
nicotinamide site would assist cyclization and hydrolysisspecificity. The substitution of cysteine in place of glu-
tamic acid at position 98, which appears in mouse BST-1, by shunting of nicotinamide out of the active site and
clearing Trp140 for the binding of the purine group ofmay lead to a loss of specificity for cyclization or nicotin-
Structure
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tic scheme, mouse BST-1 does not share either property
with cyclase, so that the cyclization reaction is impaired
with respect to both CD38 and cyclase. The identifica-
tion of a BES trapped covalent intermediate implies that
BES release may play a role in determining cyclization
versus hydrolysis; it is unclear how BES binding to
Trp140 blocks hydrolysis, such binding apparently
blocks cyclization sterically.
A general reaction model for the protein family pro-
ceeds from the understanding of the enzymatic mech-
anism of cyclase, and future experiments can be
proposed which will better explain the biochemical dif-
ferences between cyclase, CD38, and BST-1. For exam-
ple, nicotinamide binding properties can be assayed
with tryptophan fluorescence experiments. General cy-
clization and hydrolysis inhibitors might target the inner-
most nicotinamide site which is shared by all the pro-
teins in this family. ADP-ribosyl cyclase activity canFigure 8. Comparison of Cyclase and BST-1 Structures and CD38
presumably be modulated by agents designed to specif-Model
ically target the second nicotinamide site, which mayThe cyclase subunits are colored blue, green, and red, from the N- to
C-terminal respectively, and the side chains are shown in ball-and- reduce cyclic product while leaving other cyclase activi-
stick representation with yellow carbon, blue nitrogen, red oxygen, ties unaffected. Moreover, the pursuit of CD38 and addi-
and violet phosphorus. BST-1 is colored gray, and the BST-1-based tional inhibitor-bound structures at higher resolutions
CD38 model is colored pink. E78 of BST-1 conflicts with the phos- may lead to improved reagents and mechanistic in-
phate group of R5P in the current structure, which may indicate an
sights, which could be of therapeutic interest.impeded tendency toward cyclization with respect to cyclase and
CD38, both of which have a serine residue in this position. The CD38
Experimental Proceduresmodel is more similar to cyclase than to BST-1 in the region of the
cyclization cleft surrounding R5P (cyclase-based model not shown).
Crystallization, Data Collection, and Molecular ReplacementIn contrast, CD38 and BST-1 are similar in the region of the second
The preparation of triclinic nicotinamide-bound Aplysia ADP-ribosylnicotinamide site of cyclase in that W111 is blocked by I133 or V136
cyclase crystals with unit cell dimensions a  60.4 A˚, b  75.3 A˚,respectively. Thus, it appears that CD38 shares properties affecting
c  138.1 A˚,   88.2,   89.2, 	  89.1, and the details ofcyclization with cyclase, but CD38 also shares properties affecting
data collection and molecular replacement solution were previouslynicotinamide binding with BST-1. The proteins are shown in ribbon
described (Munshi et al., 1999). Since that time, monoclinic cyclaserepresentations. Key residues appear as ball-and-stick, and the N-ter-
crystals with unit cell dimensions a  70.3 A˚, b  58.3 A˚, c  72.4 A˚,minal loops are truncated at the first helix for clarity purposes. The
  100.7 have been grown under conditions similar to the triclinicfigure was rendered with the program Raster3D (Merritt and Bacon,
crystals and in the presence of the BES compounds, such as pyri-1997).
dylcarbinol, or in the presence of NGD. The monoclinic crystals were
grown by seeding at 18C from a mixture of 2 l protein solution
and 2 l reservoir solution (0.1 M imidazole [pH 7.5] and 12%–24%
the cyclization substrate. Thus, an analysis of the current PEG 4K). The partial specific volume (Matthews, 1968) was similar
structures predicts that CD38 would be similar to BST-1 for both crystal forms (2.7 for triclinic, 2.5 for monoclinic), corre-
sponding to eight and two molecules of 29 kDa per asymmetric unitin nicotinamide binding, but nicotinamide release at
respectively for the triclinic and monoclinic crystals. The monoclinicTrp140 would be similar to cyclase due to the presence
structures were solved by molecular replacement with the programof the crucial residue, Glu98.
AMoRe (Navaza, 1994), using the original cyclase structure (Prasad
et al.l., 1996) as a search model, and the triclinic nicotinamide-
bound structure (Munshi et al., 1999) has been refined to finality.Structural Comparison of Enzymatic Mechanisms
All data were collected at MacCHESS with 
  0.93 A˚ on beamlinefor Cyclase, CD38, and BST-1
stations A1 and F1 using a Quantum 4 CCD detector, and the sta-These high-resolution structures, combined with com-
tistics of data collection and unit cell parameters are shown in
parison to the structure of BST-1 (Yamamoto-Katayama Table 1.
et al., 2002) and to our CD38 model, have provided for
a detailed understanding of the cyclization mechanism Structural Refinement and Quality
The crystallographic refinement, molecular modeling and building,and a structural explanation of the relative enzymatic
and molecular graphics calculations were performed using an Appledifferences which supports the known biochemical
dual-processor G4 minicluster running the GNU-Darwin Distributionproperties of this crucial protein family. In particular, the
(http://www.gnu-darwin.org/). After an initial round of maximum like-differentiation of relative tendency toward cyclization
lihood positional refinement and simulated annealing using the pro-
versus hydrolysis and stabilization of the covalent inter- gram CNS (Bru¨nger et al., 1998), the R factor fell to levels indicating
mediate can all be explained based on the structures a correct solution (25.21%, 25.74%, 25.72%, and 26.96% for the
pyridylcarbinol-bound, nicotinamide-bound, native, and mutantand on specific sequence differences. Overall, the CD38
structures respectively). The various ligands were built into the re-model shares one of two cyclization-promoting proper-
sulting simulated annealing omit maps, and a regimen of maximumties with cyclase: it has a strong hydrogen bond accepor
likelihood phase refinement was applied, followed by an automated(Glu98) near the active site but not a second nicotin-
refinement procedure using ARP/WARP (Lamzin and Wilson, 1993)
amide site, so that CD38 is expected to have similar combined with multicrystal and noncrystallographic symmetry aver-
cyclization and hydrolysis chemistry to cylase, but dif- aging using the program DM (Cowtan, 1994). The program PyMOL
(http://pymol.sourceforge.net) was used for crystallographic struc-ferent nicotinamide binding properties. In this mechanis-
Covalent Intermediate in ADP-Ribosyl Cyclase
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Table 1. Data Collection and Refinement Statistics
Data Collection Statisticsa
Pyridylcarbinol Nicotinamideb Native Mutant
Resolution range (A˚) 24–2.0 (2.1–2.0) 33–2.4 (2.6–2.4) 25–1.7 (1.8–1.7) 20–2.0 (2.1–2.0)
Rsym (%) 9.0 (20.0) 10.8 (31.0) 5.4 (28.0) 8.6 (25.5)
Completeness (%) 99.5 (96.6) 88.0 (44.7) 99.1 (99.1) 99.7 (98.6)
Redundancy 3.4 3.9 3.3 3.8
Crystallographic Parameters
a b c   	 Space Group
Pyridylcarbinol 70.3 A˚ 58.3 A˚ 72.4A˚ 90 100.7 90 P21
Nicotinamideb 60.4 A˚ 75.3 A˚ 138.1A˚ 88.2 89.2 89.1 P1
Native 70.3 A˚ 58.3 A˚ 72.4A˚ 90 100.8 90 P21
Mutant 70.3 A˚ 58.3 A˚ 72.4A˚ 90 100.7 90 P21
Crystallographic Refinement Statistics
Pyridylcarbinol Nicotinamideb Native Mutant
Number of reflections 38,943 57,197 61,981 35,252
Sigma cutoff none none none none
R factor (%) 21.20 24.39 20.77 22.94
Free R factor (%) 25.18 26.94 23.79 26.13
Monomers per asymmetric unit 2 8 2 2
Ligands R5P, pyridylcarbinol R5P, nicotinamide none none
Total number of waters 92 0 276 66
Rms deviation from ideal
Bond lengths (A˚) 0.0179 0.0139 0.0185 0.0152
Bond angles () 1.8143 1.6915 1.8650 1.727
a Outer shell statistics in parentheses.
b Munshi et al. (1999).
ture building. In the last step, the models were refined using CNS Received: April 25, 2003
Revised: November 12, 2003and display good stereochemistry as judged by the programs CNS
and PROCHECK (Laskowski et al., 1993). The final refinement and Accepted: November 13, 2003
Published: March 9, 2004stereochemical statistics are shown in Table 1.
The automated refinement procedure in combination with averag-
ing produced striking improvements in the electron density map, References
so that ribose-5-phosphate was clearly identified in the catalytic
groove of the pyridylcarbinol- and nicotinamide-bound enzymes Aarhus, R., Graeff, R.M., Dickey, D.M., Walseth, T.F., and Lee, H.C.
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amide site (Munshi et al., 1999). This observation is supported by Grosse-Kuntsleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, N.,
the observation of reagent hydrolysis in ADP-ribosyl cyclase (Figure Pannu, N.S., et al. (1998). Crystallography and NMR system (CNS):
5), and by the recently published BST-1 structures (Yamamoto- a new software system for macromolecular structure determination.
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